1. Home
  2. NTLA vs MTTR Comparison

NTLA vs MTTR Comparison

Compare NTLA & MTTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • MTTR
  • Stock Information
  • Founded
  • NTLA 2014
  • MTTR 2011
  • Country
  • NTLA United States
  • MTTR United States
  • Employees
  • NTLA N/A
  • MTTR N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • MTTR Computer Software: Prepackaged Software
  • Sector
  • NTLA Health Care
  • MTTR Technology
  • Exchange
  • NTLA Nasdaq
  • MTTR Nasdaq
  • Market Cap
  • NTLA 1.4B
  • MTTR 1.5B
  • IPO Year
  • NTLA 2016
  • MTTR N/A
  • Fundamental
  • Price
  • NTLA $13.80
  • MTTR $4.78
  • Analyst Decision
  • NTLA Buy
  • MTTR Hold
  • Analyst Count
  • NTLA 17
  • MTTR 4
  • Target Price
  • NTLA $56.63
  • MTTR $5.13
  • AVG Volume (30 Days)
  • NTLA 3.1M
  • MTTR 1.9M
  • Earning Date
  • NTLA 11-07-2024
  • MTTR 11-12-2024
  • Dividend Yield
  • NTLA N/A
  • MTTR N/A
  • EPS Growth
  • NTLA N/A
  • MTTR N/A
  • EPS
  • NTLA N/A
  • MTTR N/A
  • Revenue
  • NTLA $43,086,000.00
  • MTTR $165,426,000.00
  • Revenue This Year
  • NTLA $50.73
  • MTTR $11.03
  • Revenue Next Year
  • NTLA $8.69
  • MTTR $14.24
  • P/E Ratio
  • NTLA N/A
  • MTTR N/A
  • Revenue Growth
  • NTLA N/A
  • MTTR 3.82
  • 52 Week Low
  • NTLA $12.82
  • MTTR $1.73
  • 52 Week High
  • NTLA $34.87
  • MTTR $4.99
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 36.15
  • MTTR 56.69
  • Support Level
  • NTLA $12.82
  • MTTR $4.59
  • Resistance Level
  • NTLA $17.30
  • MTTR $4.88
  • Average True Range (ATR)
  • NTLA 1.11
  • MTTR 0.12
  • MACD
  • NTLA -0.11
  • MTTR -0.00
  • Stochastic Oscillator
  • NTLA 19.56
  • MTTR 76.19

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About MTTR Matterport Inc.

Matterport Inc is a spatial data company focused on digitizing and indexing the built world. Its all-in-one 3D data platform enables anyone to turn a space into an accurate and immersive digital twin which can be used to design, build, operate, promote, and understand any space. The Company recognizes revenue from subscription, license, services and sale of products. Majority of the revenue is generated in the form of subscription fees which it receives from the customers for providing them access to Matterport platform.

Share on Social Networks: